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Six ty- seven patients, 19 fem :ll es and 48 m ales, 4-66 yea rs 
o ld , suffe rin g fro m lesions o f cutaneous leishma niasis 
were trea ted to pi ca ll y with an o intm e nt comprisin g 15% 
paro m o mycin sulfate and 12% m eth ylben ze thonium chl o-
ride in white soft pa raffin (P-ointment, U .K . patent 
GBll7237A). Afte r 10 d ays of treatm ent , twi ce daily , the 
les io ns in 72% of the treated pati ents were free of parasites, 
15% beca m e free with in an addition al 20 d ays, witho ut 
further trea tment, and 13% failed to respond . Pig m entation 
d evelo ped in 18% of the trea ted lesio n s and inAammatio n 
of varying degree was associated with t he treatm ent. T hese 
Leishmaniasis is a diso rder produ ced by Aagelbted pro-tozoa of the genus L eis/lll1allia. Depending on the ca us-ative species, th e disease Ill ay m anifest itse lf as a sys-tellli c, a destructive mu cocutaneo us, o r a purely cutaneo us chroni c in fection. AII 3 forms are translilitted 
by species of sa ndAi es belong ing to the genus Phlevolo/III.IS (O ld 
World) o r the genus LlI lz o/llia (New World). 
L eishlllania //"Iajor, one of the eti o logic agents of cutaneous lei sh-
mani as is (Cl) in the O ld World , prod uces in hum ans a se lf-
hea ling les ion fo ll owed by long-las ting immunity to reinfecti on 
1"1] . The introdu cti on of the paras ite into the skin is fo ll owed by 
the development of a pap ul ar lesion w hi ch may enlarge and ul-
cerate and persist fo r up to 18 months. Spontaneous reso lution 
of a large lesion often lea ves an unsightl y sca r. Both sexes and 
all ages are susceptible. 
C utaneous leishmani as is is of clini ca l importance beca use of its 
chroni city and its potenti al for loca l des tru ction and disfigure-
ment. N o sa tisfacto ry systemicall y ad mini stered drug against th e 
disease has yet been developed; reli ance is on a few drugs w hich 
are sometimes ineffecti ve and may be associated w ith side effects. 
The need for effi cacious, more easil y admini stered, and less tox ic 
antiicis hmania l agents is req uired. Rifampicin was the first o rall y 
effective antileishmanial agent introduced to clini ca l medicine 12-4]. 
Other o ral med ica ti on, sLi ch as metronidazo le 15-7] and co-tri-
moxazole [8,91 showed controve rsial effi cacy against the disease . 
The develop ment of the new antifungal agent ketoconazole may 
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Abbreviatio ns: 
C L: cutan cous Icishm an.iasis 
LRC: Leis/lIl/fIIl ia I{cfcrcncc Ccnter 
M 13 I: Ill cthy lbcnze thoni um chlor ide 
PR: paromomycin sul phate 
d eve lo pm ents did not affec t th e clinica l he:din g process 
which was genera ll y co mpl e ted in a period of 10-30 d ays 
after te rmination of trea tm ent . In add ition, 94% of the 
trea ted lesio n s healed with little o r no sca rrin g. N o adverse 
cli ni ca l or laboratory side effe cts w ere observed except fo r 
a burnin g sensation at th e site of trea tm ent. Parasites iso_ 
lated fr o m patients w ho failed to respond to topica l trea t_ 
m ent were found to be susceptible to PR-MBC I in both 
in vitro infected m acropha ges and in vivo in experimenta lly 
infected BALE /c mi ce. J In vest Dennato/ 87:284-288, 1986 
prove to be a maj or antil eishmanial th era peuti c advance aga inst 
bo th cutaneO Ll S and mucocutaneous leishmaniasis [1 0, 111. 
Although C L is purely a skin disease, very fe w studi es have 
been made to develop a simple topi cal application for its treat-
ment. Loca l treatment with imidazole derivatives was found to 
be ineffective in curin g CL ca used by either L. lIIajor or L. lIIex icana 
a/llaZOIl ClIsis in both ex perimental anim.als and humans 11 21. H ow_ 
ever, a chJ orpro l11azine-containin g ointment was recentl y u sed 
successfull y in hea ling diffuse CL du e to L. (/clhiop ica in hUlllan 
1 13J. 
In a prev ious study , an o intment containing parom omycin and 
methylbenzeth onium chlo rid e was fou nd to be hi ghly effecti ve 
in curing CL in experimental animals [14]. All mice infected w ith 
L. lIIajor LRC-LJ37 were cured of the cutaneous disease after local 
treatment applied twice daily fo r 6-10 days. The paras ites were 
tota ll y eliminated from th e lesions, w hich rapidly healed. The 
present study describes the effi cacy of similar topica l treatlllent 
in humans aga inst CL ca used by L. I/Iajor. 
MATERIALS AND METHODS 
Patients, Treatment, and Evaluation of Responses Sixty_ 
seven patien ts of both sexes and different ages with ea rl y and 
adva nced infection were trea ted (Tab le I). The number of lesions 
per patient was '/-39. In most cases only one, th e largest and 
most act ive les ion , was trea ted while either one or more other 
untreated lesions on the same patient se rved as contro l. The le-
siollS were trea ted with an ointment containing 15% parom o-
m ycin sulph ate (PR) and 12% mcthylbenzethonium chloride 
(MBCI) in white soft paraffi n (P-ointmcnt), twice daily fOr a 
period o f 1 ° days. All ointment preparations were manufactured 
and supplied by Teva Pharmaceutical Industries Ltd. , Jerusal em. 
In several cases th e treatment was extend ed for another 10 da 
and in one patient th e trea tment was given for a period of 2 
days . Treated lesions were generally left un covered, but in a few 
cases the lesions were cove red by adhes ive tape (Dermiciear) to 
prevent clo thin g or dirt contam ination. Between treatments the 
lesions were w iped clean. 
The results obtained were defined as follow s: (1) rapidl y ef-
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Table I. Results of Topica l T rea tm ent w ith P-Ointment on C utan eous Leish n1Jniasis 
Description of Patien ts 
Effect of 
Age (years) 
Treatment 5ex N o. Percent Average ± 5D 
Rapidly effective M 34 50.7 24.34 ± 8.6 
F 14 20.8 23.23 ± 14.0 
Less effect ive M 6 8.9 29.83 ± 12.2 
F 4 5.9 29.75 ± 20.2 
Ineffecti ve M 8 11. 9 21.1 5 ± 10.3 
F I 1.5 25.00 ± 0.0 
fect ive: no parasites were detected in the treated les ion at th e cnd 
of 10 days of treatm ent; (2) less rapidl y effective: para si tes werc 
still presen t in the treated lesion at the cnd of l 0 days of trea tl11 cnt, 
but disa ppeared w ithin the nex t 20 days; (3) ineffecti ve: paras ites 
still present in the lesions at least 1 month after the end of tre:J[-
ment. 
Diagnosis and Laboratory Examinations In all cases the di-
agnosis was based on posit ive smea r and/ o r cultures . La rge les ions 
were examined at severa l sites. Fo r smear and culture preparations 
the lesion was first cleaned with 70% eth ano l. Material aspirated 
with a fine Pasteur pipette through a sm all incision made at th e 
margin of the les ion with a sterile surgica l blade was stained with 
Gie msa and cultured in N . N .N . blood-aga r medium. In mu ltiple 
infecti on 1-4 lesions o f the same patient were subjected to par-
as ito logic eva luation and used as co ntro l. T he cul ture was incu-
bated at 28°C and the development of li vin g promas tigotes was 
determined. C ultures were conside red nega tive only after 20 days 
w itho ut growth. Protozoal exa minations were perfo rm ed prio r 
to, at the end of, and every 2 weeks afte r te rmin at ion of treatment. 
The paras ites were identified as Leishlllallia lIIajor (formerl y L. 
tropica lII ajor) by the isolated paras ites excreted facto r (EF) sero-
typing '1 5] and characterization of enzy mes by electrophoresis 
[16]. 
Routi ne laboratory exa minations co mpri sin g blood sed imen-
tation rate, differential blood coun t, blood biochemistry including 
li ver fu nction tests, and urin alysis were done prio r to and on 
completion of trea tm ent. 
Determination of Paronlomycin Coneentration in Serum 
The mi crobio logic inhibition zone method, described by Arret 
e t al [17], was adopted for meas urin g paromo m ycin concentration 
in the serum of pati ents treated with P-o intment. T he zones of 
in hib ition produced in a Petri dish covered w ith aga r medium 
and seeded w ith a Staphylococc/ls cpiderlllidis ATCC 12228 cul ture 
around a 100-fLl sa mple of serum to be assayed were eva luated. 
Sera were collected 1, 4, and 24 h after term ination of 10 days of 
treatment. 
Resistance and Susceptibility of Parasites to Paro-
momycin Pron'las ti gotes cultured f!'Om lesions w hi ch re-
sponded poorly to topica l trea tment were used to infect C3H 
mouse peritonea l m acro phages in culture at 37°C and also the 
base of the tai l of BALB/c mice as previously described [1 4,18 ]. 
In the in vitro stud y, the infected ma cro phages were exposed to 
paromomycin at 100 ILg/m l for 4 days and the effect on the 
intracellular am astigotes was examined microscopically in Giemsa-
stained preparations. In the in vivo stud y, the base of th e ta il of 
the mice was inoculated with 2.5 x 10" promastigotes. Approx-
imately 45 days afte r infection the les ions that had developed at 
the site of infection w ere treated w ith P-ointment, twi ce dai ly for 
a period of 10 days. T he presence of viab le parasites in the treated 
lesions was mon itored microscopicall y in both smears and cul-
tures as previously described [14] . 
Da ys from Appearance of 
Lesion ro O nset of 
Treatment No. of Lesions per Patient 
Ran ge Average ± 5D Ran ge Average ± 5D Range 
19- 55 86.09 ± 43.9 30-240 6.H7 ± 5.6 1- 19 
19-66 120.38 ± 77.3 30- 270 5.7 1 ± 3.5 1- 12 
19-4·<) 78.33 ± 58.4 60- 180 10. 16 ± 9.8 3- 39 
19-60 100.00 ± 34.6 60- 120 8.50 ± 8. 1 1-20 
2- 36 96.25 ± 38.9 60- 180 8.25 ± 8.9 1- 29 
25 250.00 ± 0.0 250 2.00 ± 0.0 2 
RESULTS 
T he effcct of topica l treatment w ith P-ointmcnt as determin ed 
by smcar and cul tu re techniques in 67 pati ents is summ arized in 
Tab le I. After 10 da ys of treatment, rapid clearin g was obtained 
in 48 (71.6%) pat ients. Less rapid clearing was demonstrated in 
10 (14.9%) and no effect was obscrved in 9 (13.4%) of the treated 
patients. In the rap idl y clearing g roup , parasites were tota ll y elim-
inated from the lesions by the end of the treatment and the les ions 
were clinica ll y hea led within an add itiona l 10-30 days. In mos t 
cases, at the end of the treatment parasites were eliminated only 
fro lll the treated les ions, w hi le the untreated les ion (s) of the sa me 
patient still co ntained livin g parasites. Age, sex , size of the les ion, 
and durati on since infection, as well as the presence of crusts and 
bacteri al contamination did not influence the respo nse to treat-
ment. Compari son of trea ted and untreated lesions of the same 
pati cnt in a " rapidl y clea red " g roup , who have more than I lesion 
and only 1 of them has been treated w hile the o thers were left 
untreated and used as contro l, is g iven in Fig 1. T he resu lts ob-
tai ned indicated that the rate of protozoal clea ran ce in the "rapid ly 
cleared" group was signifi ca ntl y fas ter for treated lesions tha n for 
control lesions of the sa me patients durin g the first 20 days after 
termination oftre;Jtment. Furthermore, w hi le 100% of the treatcd 
lesions were clea r of parasites 20 days after te rmination of treat-
ment, 100% clearance was ob tai ned w ith the untrea ted control 
les ions of th ese patients onl y after 60 days . T he sign test fo r 2 
related sa mples indicated that thc ratc of protozoa l clearance of 
the les ions that responded to trea tm ent was signifi can tl y faste r 
tha n that of the contro l les ions. O intment comprising 15% PR 
and 1% MBCl fa iled to cure C L infcction after 10-20 da ys o f 
treatmcnt. In th e " ineffective" g roup , hea ling of the lesions was 
achieved on ly w ithin 3-1 8 months afte r term ination of treat ment. 
Histologic and Laboratory ExaUlinations Generall y the 
clinical appeara nce of th e lesion during and at the cnd of treatment 
was worse than at th e start. Various degrees of inflammation, 
depending on the lesion size and the hos t response, were asso-
ciated w ith this treatment. Pigmcntation developed in 17.6% of 
the treated les ions and severa l weeks to I yea r were req uired for 
its reg ress ion. However, all these developments d id no t influence 
the hea ling process w hich was genera ll y completed within a pe-
riod of 10-30 da ys after termin ation of treatment (Fig 2). It was 
no table that only 6% of the treated les ions reso lved w ith marked 
scarrin g as compared with 94% of the untreated control lesions 
(Table 11). Routine labo rato ry examinations indicated no adverse 
side effects . A burning sensa tion at the site ofrrea tm ent so meti mcs 
occurred durin g the fi rst few ointment appli ca tions. 
Bioassay usin g SraphylococC/is epidenlliridis, a test scnsiti ve to 0.1 
p,g/ ml of paromomycin, fa iled to detect the drug in the sera of 
treated patients, 1, 4, and 24 h after d rug ad ministra tion. 
Microbial Susceptibility and Clinical Response to Paro-
momycin Four of the 9 patients w ho responded poorly to 
treatment ("ineffective") were highl y reactiv e to the infection, 
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Figure 1. Percentage of parasite clearance from a single treated and single 
untreated lesion on each patient from a group of 25 patients wi th CL 
designated ·'rapid hea lin g" after treatment wi th P-ointment. Drop-out of 
patient attendance fell from 25 to 5 patients during the time of exami-
nation . 
with well-developed granulomata at the inoculation sites. In these 
cases only partial clinical improvem ent was observed and the 
parasites were detectable even after 28 days (1 case) of treatment. 
The other 5 patients suffered from 1-11 sim pie cutaneous lesions 
located on th e nose, arm s, hands, legs, elbow, neck, and chin . 
Generally lesions on the tip of the nose responded slowly and 
poorly to topical treatment with P-ointment. 
Studies in vivo in experim ental animals showed that parasites 
isolated from ' '' ineffectively'' treated patients were as susceptible 
to parom omycin as those from patients success full y responding 
to trea tm ent . Total eliminati on of intracellular am astigotes was 
achieved in vitro with all the 4 isolates studi ed within 4 days of 
exposure to 100 ILg/ml PR, and all the infected BALB/c mi ce 
were completel y cured of the cutaneous disease after application 
of the ointment twice dail y for a period of 10 days. N o relapse 
of th e disease was no ted in these mi ce over the next 60 days. 
DISC USSION 
In the present study of the efficacy o f a new topica l trea tment of 
CL, the instru ctions of the WHO report [1 9] were foll owed in 
most cases. Apart from 2 patients who had previously been un-
successfully treated by intralesional infiltration of Pentostam, none 
of the patients participatin g in this s tud y had received any antl-
leishmanial treatment prior to the start of the topical treatment . 
Systemic dru g trea tment of CL is limited to only a few com-
pounds, of which th e pentava lent antimonial compounds, Pen-
tostam and Glucantime, given either i. v. or i.m ., are considered 
the first drugs of choice [20]. Although generall y well tol erated 
and associated with only minor side effects, these drugs should 
be g iven under hospital ca re. Drugs that have the advantage of 
being given o ralJ y, such as ketoconazo le and rifampicin , have 
features which m ay so metimes limit their clinica l usefuln ess and 
the resu lts in leishmaniasis are va riable. 
In the stud y described, almost 72% of the 67 patients treated 
with P-ointment were clear of paras ites after 10 days of treatment 
and another 15% cleared within an additional 20 days. After th e 
end o f the treatment, clinical improvem ent occurred rapid ly with 
most patients beco min g free of inflammation w ithin 10-30 days . 
N either th e number of lesions nor the duration of the disease 
correlated with the response rate. Furthermore, treatment of 1 
les ion affected the hea ling of o ther untreated lesions of the sa me 
patient showing to tal clea rance of these lesions w ithin 60 days 
after termination of treatment. During this period all the patients 
in the " ineffective" group remained infected . In this group com-
plete hea ling of the lesions was achieved onl y 4-16 months after 
termin ation of treatm ent. 
In human leishmaniasis the host reaction is considered to be 
predo minantly cell mediated and humoral fac tor apparently plays 
onl y a second ary role [1] . The fact that the parom omycin level 
was und etectable in patients' sera indi cates a limited penetration 
of the dru g and suggests that th e rapid healing of th e untreated 
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Figure 2. A patient with C L before and after treatment with P-ointmenr. 
The lesion was treated twice daily for 10 days. The ",,/libel'S are days after 
infection, whereas the ,,,,,,,bers wi/hi" pnl'OIlIheses are days after termination 
of treatment. 
lesion is a result of immune response ac tivation. (Paromomycin 
concentration in serum at therapeutic dose as determined by oth-
ers is 5-12 ILg/ml [21 ,22].) This hypothesis is furth er supported 
by our previous study with BALBlc mice [14] . These mice are 
highly susceptible to infection with L. major and suffer from 
visceral and lethal disease [23]. In these mice trea tment of a leish-
VOL. 87. NO.2 AUGUST 1986 
Table II. Effect of Topical Treatment w ith P- Ointment on 
th e Development of Scars and Pig m entation 
Treated Untreated 
(total no. of lesions = 34) (tota l no. of les ions = 100) 
Deep Superficial No Deep Superficial No 
Scars Scars Scars Scars Scars Scars 
Number 2 10 22 94 4 2 
of lesions 
Percent 5.9 29.4 64.7 94 4 2 
Twcnt y-nine pa tients werc exa mined wit h lesion durations of 30 (3 patients). 60 
(4 patients). 70 ( II paticnts). 120 (8 paticnts). and 180 (3 paticnts) da ys. 
manial lesio n due to L. major ca used elimination of parasites only 
from the trea ted les io n and almos t no effect was o bserved on the 
untreated lesio ns of the same animal [14] . Furthermore, g uinea 
pigs, a labo ratory model for cutaneous leishmaniasis, infected in 
both ears with L. cllriellii were clear of para sites on the treated, 
right, ea r after 10 days of trea tment with P-ointment [24] . A 
delayed effect was also o bserved on th e untrea ted lesion on the 
left ear. Those beca m e clear of paras ites 30 days after the last 
treatment of the right ea r. Such an effect was no t observed in 
highly susceptible g uinea pigs with well-developed lesions and 
metastases. In addition , treatment given at d iffe rent times after 
infection neither sto pped nor abo lished antibody production and 
delayed type hypersensitivity development, and their level 13 
, weeks after infection was hig her in the treated animals as com-
pared w ith the untreated, spontaneously cured g uin ea pigs. Sim-
ilar phenomena were also described by Bassiouny et al [25] in 
patients suffering from multiple infectio n with L. //Iajo l' treated 
by cryotherapy. T hese authors suggested that the loca l treatment 
ca using damage to the parasites is fo llowed by the release o f 
leishmanial antigenic constituents, evoking an immune response 
and leading to the regression of lesions in distant sites of the body. 
These findin gs are of considera ble interes t, particularl y in endemi c 
~ areas w here patients are exposed to reinfection. Reinfection is a 
common problem in treated leishmanias is, mainl y if the trea tment 
is given before the development of effective immune response 
[26] . Indeed , the effectiveness of to pical trea tment o n developing 
res istance to reinfection in humans needs to be carefull y exa mined. 
However, in multiple infection of 1 o r mo re lesions, the simplest 
ones could be left un treated to allow self-curing and to assure the 
, development of effective immune response. 
As in our previous work in experim ental animals [14], the 
present study indicated that th is short period of treatment was 
suffi cient to clear the lesion of both the leishmanial parasites and 
of any secondary infection, mainly bacterial, acco mpanying this 
disease; the healing was achieved 10-30 days after termination of 
treatment. 
No difference in respo nse to to pical trea tm ent was observed 
between previously untreated pa tients and those who had re-
sponded inadeq uately to previous antileishmanial agents. In ad-
dition , within th e time frame of thi s stud y no relapse fo llowing 
success ful trea tm ent (rapidl y effective and less rapidl y effective 
g roups) with P-ointment was recorded over a period ranging 
fro m severa l months to 4 years after termin ation of treatment. 
A lso none of the trea ted patients who are li ving in endemic areas 
has been reinfected. However , 9 of 67 patients were considered 
as treatment failures . Four o ut of these 9 patients had large lesions 
w ith g ranulo m ata which might have decreased the penetration of 
the drug and therefore redu ced dru g efficiency. In 1 patien t of 
this group, prolonga tion of the trea tment from 10- 28 days had 
no significant effect o n the paras ites. In terestingly, parasites iso-
lated from patients who fai led to respond to topical treatment 
f with P-ointment were found to be highly susceptible to para-
momycin-methylbenzethonium chloride in vitro in infected mac-
rophages and in vivo in ex perimental animals. It mig ht be that 
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host susceptibility rather than parasite resistance is responsible for 
the variable results obtained with patients. It is possible that the 
immunologic sta te of the host affects no t only the clinical pattern 
of this disease [27], but also plays an important role in the effi cacy 
of the treatment [28]. 
Diffuse C L, recurrent CL, and chronic CL are likely to occur 
in individuals w ith an impaired immune res ponse m echanism 
[28]. These diseases are difficult to treat and are often resistant to 
conventional therapy [28]. H enriksen and Lende [1 3] described 
the effectiveness of chlorpromazine ointment in healing diffuse 
CL due to L. aelhiop ica and w e showed the efficacy of P-ointment 
in curin g recurrent CL caused by L. Il'Opica [29]. The present 
work ex tends these resul ts to sim ple CL ca used by L major. Areas 
th at sti ll req uire clarification include optimum dosage and sched-
ule techniques. Altho ugh further data must accumulate before 
definite statements on the relative effi cacy of this treatment can 
be m ade, it see ms that this topical treatment m ay prove to have 
a promising future in the treatment of CL. 
The alllhors Ihallk Blallen MOlllillo jiJr her lechllical assislallce . 
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